A role for lipoxygenase metabolites of arachidonic acid in porcine ovulation.
Prostaglandins, products of arachidonic acid via the cyclooxygenase pathway, are essential to the porcine ovulatory process in that inhibition of their synthesis results in ovulation failure. Studies in the rat have shown that ovulation is also preceded by a rise in three ovarian hydroxyeicosatetraenoic acids, products of the lipoxygenase pathway, and inhibition of this pathway also inhibits ovulation. Experiments were designed, using a pregnant mare serum gonadotropin/human chorionic gonadotropin (hCG)-treated prepuberal gilt model, to measure pre-ovulatory changes in follicular fluid concentrations of 15-hydroxyeicosatetraenoic acid (15-HETE), and to compare the effects of indomethacin and nordihydroguaiaretic acid (NDGA) on ovulation in the pig and on 15-HETE and prostaglandin F2 alpha synthesis both in vivo and in vitro. Follicular fluid concentrations of 15-HETE were elevated significantly just prior to the expected time of ovulation (40 h after hCG). When indomethacin (10 mg) was injected into the ovarian stalk at 24 h after hCG, follicular fluid concentrations of both 15-HETE and prostaglandin F2 alpha were lower (P < 0.01) than controls at 40 h and ovulation rate was suppressed (P < 0.01). When NDGA (5 mg) was administered in the same manner, ovulation rate was suppressed (P < 0.01), but the levels of 15-HETE and prostaglandin F2 alpha were not altered. Synthesis of 15-HETE by cultured granulosa and theca interna cells was reduced by the presence of NDGA (1 mg/ml), whereas indomethacin (100 ng/ml) lowered 15-HETE production in theca interna cells only. These results clearly demonstrate that indomethacin can block the lipoxygenase as well as the cyclooxygenase pathways, depending on the dose used, and suggest that lipoxygenase metabolites of arachidonic acid are involved in the ovulatory process in the pig.
Downey
B R
BR
Department of Animal Science, McGill University, Ste. Anne de Bellevue, Quebec, Canada. downey@agradm.lan.mcgill.ca
Mootoo
J E
JE
Doyle
S E
SE
D000818:Animals; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D015331:Cohort Studies; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D015237:Dinoprost / Q000032:analysis*; D005260:Female; D015571:Follicular Fluid / Q000737:chemistry / Q000187:drug effects; D006064:Gonadotropins, Equine / Q000008:administration & dosage; D006107:Granulosa Cells / Q000737:chemistry / Q000187:drug effects; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000032:analysis* / Q000378:metabolism; D007213:Indomethacin / Q000008:administration & dosage / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology*; D009637:Masoprocol / Q000008:administration & dosage / Q000494:pharmacology; D006080:Ovarian Follicle / Q000737:chemistry* / Q000166:cytology / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects / Q000502:physiology*; D010062:Ovulation Induction / Q000379:methods; D011897:Random Allocation; D013552:Swine / Q000502:physiology*; D013799:Theca Cells / Q000737:chemistry / Q000187:drug effects; D013997:Time Factors
D006063:Chorionic Gonadotropin; D016861:Cyclooxygenase Inhibitors; D006064:Gonadotropins, Equine; D006893:Hydroxyeicosatetraenoic Acids; D016859:Lipoxygenase Inhibitors; C025984:15-hydroxy-5,8,11,13-eicosatetraenoic acid; D009637:Masoprocol; D015237:Dinoprost; D007213:Indomethacin